KalVista reports PhIII success of on-demand, oral hereditary angioedema drug as it seeks to challenge injectables

Lei Lei Wu

News Reporter

KalVista Pharmaceuticals’ oral medicine for hereditary angioedema helped relieve attack symptoms associated with the disease substantially faster than placebo in a late-stage study, setting the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

KalVista reports PhIII success of on-demand, oral hereditary angioedema drug as it seeks to challenge injectables

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

KalVista re­ports PhI­II suc­cess of on-de­mand, oral hered­i­tary an­gioede­ma drug as it seeks to chal­lenge in­jecta­bles

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

KalVista reports PhIII success of on-demand, oral hereditary angioedema drug as it seeks to challenge injectables